Li-Jian Pang

Dr. Li-Jian Pang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Clinics
Verified
Journal Article
Open access
XZXinXin Zhang
XinXin Zhang
LPLi-Jian Pang
Li-Jian Pang
XLXiaoDong Lv
XiaoDong Lv
HZHaoYang Zhang
HaoYang Zhang
The risk factors of bronchiectasis in patients with chronic obstructive pulmonary disease have not yet been established. This systematic review and meta-analysis aimed to investigate and identify potential risk factors for patients with chronic obstructive pulmonary disease accompanied by bronchiectasis. We reviewed eight electronic journal databases from their inception to November 2019 for observational studies with no language restrictions. The Newcastle-Ottawa Scale was applied to evaluate the quality of the literature. Binary variables were pooled using odds ratios and continuous variables using the standardized mean difference with 95% confidence intervals. The confidence of evidence was assessed according to the grading of the recommendations assessment, development, and evaluation method. Eight case-control studies met the inclusion criteria. Tuberculosis history, smoking history, hospitalization stays, admissions in the past year, and duration of symptoms were considered risk factors. In addition, the ratio between the forced expiratory volume in 1s and forced vital capacity, the percentage of forced expiratory volume in 1s, the forced expiratory volume in 1s as a percentage of the predicted value, purulent sputum, purulent mucus sputum, positive sputum culture, Pseudomonas aeruginosa infection, arterial oxygen pressure, daily dyspnea, C-reactive protein, leukocytes, and the percentage of neutrophils were found to be closely related to bronchiectasis. However, these were not considered risk factors. The evidence of all outcomes was judged as “low” or “very low.” Additional prospective studies are required to elucidate the underlying risk factors and identify effective preventive interventions.

18 December 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JPJiaxiang Pan
Jiaxiang Pan
YLYue Li
Yue Li
XWXize Wu
Xize Wu
XPXue Pan
Xue Pan
CLChuang Liu
Chuang Liu
XLXiaodong Lv
Xiaodong Lv

1 April 2020 in European Journal of Integrative Medicine
Verified
Journal Article
Closed access
JZJiyu Zou
Jiyu Zou
LPLi-Jian Pang
Li-Jian Pang
XLXiaodong Lv
Xiaodong Lv

23 July 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
JWJia-Qi Wang
Jia-Qi Wang
YLYuan-Yu Liang
Yuan-Yu Liang
ZZZhong-Xue Zhao
Zhong-Xue Zhao
WXWei Xie
Wei Xie
WSWan-Ning Sun
Wan-Ning Sun
LPLi-Jian Pang
Li-Jian Pang
Background: Asthma remains a significant public health challenge globally, particularly among older adults who face diagnostic complexity, atypical symptom profiles, and frequent comorbidities. Despite global advances in asthma control, little attention has been paid to the evolving composition and geographic disparity of modifiable risk factors in this age group.Methods: We utilized data from the Global Burden of Disease Study 2021 to evaluate the long-term trends (1990–2021) in asthma burden attributable to high body-mass index (BMI), smoking, and occupational asthmagens among adults aged 60 years and older. Key metrics included age-standardized mortality rates (ASMR), age-standardized DALY rates (ASDR), and estimated annual percentage change (EAPC). Stratified analyses were conducted across Socio-demographic Index (SDI) quintiles, gender, and detailed 5-year age subgroups (60–64 to ≥95 years) to assess disparities across socioeconomic development, gender, and aging patterns, with additional stratification by geographic region.Results: From 1990 to 2021, asthma burden attributable to smoking and occupational asthmagens among older adults declined globally, while high BMI-related burden increased in several middle and low SDI regions. In terms of attribution proportion, the proportion of asthma deaths attributable to high BMI increased from 10.89 to 14.4%, with this upward trend being particularly pronounced in high SDI regions. Occupational asthmagens-related burden showed limited decline and remained elevated in low SDI regions. Gender-stratified analysis showed that the risk burden of smoking was higher in older men in Asia, whereas the high BMI-related burden was higher in women in more developed regions.Conclusion: This study demonstrates a structural shift in the composition of asthma risk factors among older adults, with high BMI emerging as a dominant contributor amid declining traditional behavioral risks such as smoking. There are significant differences among regions, age groups and genders. Targeted, region-specific strategies are essential to address these evolving risks and reduce inequities in asthma burden among aging populations.

26 February 2026 in Reviews in Medical Virology
Verified
Journal Article
Open access
NZNingzi Zang
Ningzi Zang
YWYingxu Wu
Yingxu Wu
PLPin Li
Pin Li
YLYongming Liu
Yongming Liu
SWShiwen Wang
Shiwen Wang
JWJiaran Wang
Jiaran Wang
Idiopathic pulmonary fibrosis (IPF) is a serious progressive complication of the respiratory system, which is profoundly associated with persistent extracellular matrix (ECM) deposition, fibrosis, and disrupted tissue regeneration. Emerging evidence shows that epithelial–mesenchymal transition (EMT) acts as a key factor in the pathogenesis of this idiopathic interstitial lung disease by connecting long‐lasting epithelial damage to fibroblast accumulation and fibrotic processes. Viral pathogens, particularly emerging and re‐emerging viruses, such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), Influenza Virus, and Dengue Virus (DENV) and also those with oncogenic potential such as Epstein–Barr Virus (EBV), Cytomegalovirus (CMV), and Hepatitis C Virus (HCV), have been demonstrated to be significantly associated with impaired epithelial signalling, persistent inflammation, and EMT induction. This underscores the presence of potential mechanistic overlap between viral infections and fibrotic complications of the respiratory system. On the other hand, investigations have also suggested the capacity of Traditional Chinese Medicine (TCM) agents to modulate various EMT‐linked pathways, which are simultaneously involved in both viral infections and IPF development. These common signalling pathways include TGF‐β, Wnt/β‐catenin, PI3K/AKT, and NF‐κB signalling, acting as potential therapeutic targets against fibrotic complications such as IPF. The present review aims to comprehensively describe current evidence on the dynamic cross‐talk between viral pathogens, particularly SARS‐CoV‐2, Influenza Virus, and DENV, EMT, and lung fibrosis. Additionally, it critically discusses how TCM‐derived bioactive agents can interfere with these interconnected processes. This review elucidates the mechanistic basis and therapeutic potential of TCM compounds in lung fibrosis, considering the wider context of virus‐related EMT dysregulation.

7 October 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
JLJingze Li
Jingze Li
QYQuan Yuan
Quan Yuan
RYRuizhi Yu
Ruizhi Yu
LPLi-Jian Pang
Li-Jian Pang
TWTianjiao Wang
Tianjiao Wang
XLXiaodong Lv
Xiaodong Lv
This study rigorously and comprehensively evaluated the clinical evidence of Chinese patent medicines (CPMs) in treating the stable phase of chronic obstructive pulmonary disease (COPD), highlighting problems and solutions. This study aimed to systematically evaluate the clinical evidence of 42 oral CPMs for the treatment of stable COPD using evidence mapping, identifying research trends, methodological quality, and gaps in the current literature. A comprehensive search was conducted across multiple databases, including CNKI, Wanfang, VIP, SinOMed, PubMed, Web of Science, Embase, and Cochrane Library, up to November 1, 2024. A total of 205 studies (203 in Chinese and 2 in English) were included, comprising 181 randomized controlled trials (RCTs), 8 non-randomized controlled trials (non-RCTs), 2 case-control studies, 9 systematic reviews/Meta-analyses, and 5 guidelines/expert consensuses. Data were extracted and analyzed using evidence mapping techniques, focusing on publication trends, Traditional Chinese Medicine (TCM) syndrome types, interventions, outcome indicators, and methodological quality. The analysis revealed that CPMs are extensively applied in the treatment of stable COPD and have demonstrated remarkable therapeutic efficacy. Among them, Bailing Capsules are the most researched, accounting for 26.70 % of the published studies. However, clinical indications for many CPMs remain ambiguous, and safety information is often incomplete. Methodological quality of the studies was generally low, with issues such as inadequate randomization, lack of blinding, and incomplete outcome reporting. TCM syndrome differentiation was underutilized, with only 32.46 % of studies detailing TCM syndrome classifications. Outcome measures were heterogeneous, with a focus on clinical efficacy and pulmonary function tests, but limited attention to TCM-specific outcomes and long-term follow-up. This evidence mapping highlights the need for improved methodological rigor, standardized outcome measures, and better integration of TCM theory in clinical research. While CPMs show promise in managing stable COPD, future studies should address safety gaps, enhance TCM syndrome differentiation, and conduct economic evaluations to optimize their clinical application. These findings provide a roadmap for researchers, clinicians, and policymakers to advance the role of CPMs in global respiratory medicine.